We are live on ! Find out more
AVEO

AVEO Pharmaceuticals, Inc.
AVEO

Delisted

AVEO was delisted on the 19th of January, 2023.

Back to rankings

44 hedge funds and large institutions have $16M invested in AVEO Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

0% more funds holding

Funds holding: 44 → 44 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

38% less capital invested

Capital invested by funds: $25.7M → $16M (-$9.69M)

60% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 10

Holders
44
Holders Change
–
Holders Change %
0%
% of All Funds
1.1%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
6
Increased
4
Reduced
10
Closed
6
Calls
$8K
Puts
–
Net Calls
+$8K
Net Calls Change
-$49K

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$667K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$156K
3
Renaissance Technologies
Renaissance Technologies
New York
+$99K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$26.1K
5
TSS
Two Sigma Securities
New York
+$9.83K

Top Sellers

Rank Fund Capital Flow
1
SCM
Sarissa Capital Management
Connecticut
-$200K
2
SIM
Spark Investment Management
New York
-$91.2K
3
BCM
Bridgeway Capital Management
Texas
-$35.4K
4
TRCT
Tower Research Capital (TRC)
New York
-$29.5K
5
Citadel Advisors
Citadel Advisors
Florida
-$28.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
TSS
26
Two Sigma Securities
New York
$8K +$9.83K +1,474 New
BA
27
BlackRock Advisors
Delaware
$7K – – –
VKH
28
Virtu KCG Holdings
New York
$7K +$9.03K +1,354 New
EWM
29
Edge Wealth Management
New York
$5K – – –
ECM
30
Elgethun Capital Management
South Dakota
$5K +$6.67K +1,000 New
Bank of America
31
Bank of America
North Carolina
$3K -$267 -40 -7%
Creative Planning
32
Creative Planning
Kansas
$2K – – –
TRCT
33
Tower Research Capital (TRC)
New York
$1K -$29.5K -4,426 -98%
CG
34
Cutler Group
California
$1K – – –
Manulife (Manufacturers Life Insurance)
35
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1K – – –
MFS
36
MSI Financial Services
Massachusetts
$1K – – –
CFA
37
CT Financial Advisors
Pennsylvania
$432 – – –
Citadel Advisors
38
Citadel Advisors
Florida
– -$28.9K -4,329 Closed
Acadian Asset Management
39
Acadian Asset Management
Massachusetts
– -$17K -1,911 Closed
Goldman Sachs
40
Goldman Sachs
New York
– -$15K -1,693 Closed
Millennium Management
41
Millennium Management
New York
– -$13K -1,480 Closed
Wolverine Trading
42
Wolverine Trading
Illinois
– -$11K -1,200 Closed
PCM
43
Prelude Capital Management
New York
– -$1K -100 Closed
UBS Group
44
UBS Group
Switzerland
– -$127 -19 -45%
Morgan Stanley
45
Morgan Stanley
New York
– -$60 -9 -15%
GRP
46
Global Retirement Partners
California
– +$240 +36 New
1
2

AVEO Hedge Fund Activity: Q4 2016 in Review

44 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q4 2016, worth a combined $16M — down 38% from $25.7M a quarter earlier.

Fund positioning in AVEO was balanced in Q4 2016: 6 funds opened new positions, 6 closed out, 4 added to existing stakes and 10 trimmed.

The largest buyer was 683 Capital Management, opening a new position worth an estimated $667K. The largest seller was Sarissa Capital Management, cutting an estimated $200K.

  • 44 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q4 2016, unchanged from Q3 2016.
  • Funds reported $16M of AVEO Pharmaceuticals, Inc. stock for Q4 2016, down 38% quarter-over-quarter.
  • 6 funds opened new AVEO Pharmaceuticals, Inc. positions in Q4 2016 and 6 closed out, a net change of 0 holders.
  • The largest AVEO Pharmaceuticals, Inc. buyer in Q4 2016 was 683 Capital Management, an estimated $667K added.
  • The largest AVEO Pharmaceuticals, Inc. seller in Q4 2016 was Sarissa Capital Management, an estimated $200K sold.

Based on aggregated 13F filings for Q4 2016.